重組人干擾素治療皰疹性咽炎123例療效分析

重組人干擾素治療皰疹性咽炎123例療效分析

【摘要】 目的 觀察重組人干擾素治療小兒皰疹性咽炎的臨床療效。方法 將臨床確診皰疹性咽炎的230例患兒隨機分為治療組和對照組。兩組常規(guī)預(yù)防感染及對癥治療，治療組123例患兒給予重組人干擾素1 μg/(kg次)，1次/d，肌內(nèi)注射，連續(xù)3 d；對照組107例患兒給予病毒唑10 mg/(kgd)靜脈滴注，1次/d，連續(xù)3 d。觀察治療前后患兒的臨床癥狀及體征。結(jié)果 治療組總有效率(98.38%)、熱程(3.74±2.3)d，咽部充血及皰疹平均消退時間(4.64±2.3)d，住院期(6.44±2.1)d；對照組總有效率(80.37%)、熱程(4.32±2.6)d，咽部充血及皰疹平均消退時間(6.84±2.3)d，住院期(9.3±1.1)d。治療組在退熱時間、皰疹消退時間及住院期方面明顯優(yōu)于對照組(P＜0.05)。結(jié)論 重組人干擾httP://www.stanzs.com素治療小兒皰疹性咽炎可較快改善病情、縮短病程、提高療效。

【Abstract】 Objective To explore the clinical efficacy of recombinant human interferon in treatment of pediatric herpes pharyngitis. Methods 230 patients diagnosed with herpes pharyngitis were randomly divided into treatment and control groups. Patients of two groups were treated with conventional prevention of infection and symptomatic treatment. The 123 patients of treatment group were also given recombinant human interferon (1 μg/kg, im. 1 times /d, for 3 days). 107 patiets of control group were treated with ribavirin ［10 mg/(kgd), iv.1 times/d, for 3 days］.The clinical symptoms and signs, radiological and laboratory data of these patients were retrospectively evaluated. Results In the treatment group, the overall response rate was 98.38%, the median time of thermal process was (3.74± 2.3)d, the median period of throat congestion and herpes was (4.64± 2.3)d, and length of stay (6.44± 2.1)d. In the control group, the total efficiency was 80.37%, the median time of thermal process was (4.32± 2.6)d, throat congestion and the median time of herpes was (6.84± 2.3)d, and length of stay (9.3± 1.1)d. Cooling time, the period of herpes and length of stay of patients in the treatment group was significantly better than that of patients in the control group (P＜0.05). Conclusion Recombinant human interferon in the treatment of pediatic herpes pharyngitis can rapidly improve the condition of patients and efficacy, induce the length of stay.

【Key words】 Herpes pharyngitis；Recombinant human interferon；Efficacy

皰疹性咽炎是由柯薩奇A組病毒感染所致的、小兒急性上呼吸道感染的一種特殊類型，好發(fā)于夏秋季［1］；主要治療為應(yīng)用抗病毒藥物(病毒唑)及對癥處理，預(yù)防并發(fā)癥；但既往治療療效長、副作用大［2］，使得本組考慮采用重組人干擾素治療皰疹性咽炎，現(xiàn)將觀察結(jié)果報告如下。

1 資料與方法

1.1 一般資料 2008年3月至2011年3月間經(jīng)門診收治的皰疹性咽炎確診病例230例，男117例，女113例，年齡2~15歲(平均年齡7.91歲)；并采用隨機